source
- Novartis ends mid-stage Fabhalta trial in lupus nephritis citing strategic considerationsNovartis has terminated its mid-stage trial of Fabhalta (iptacopan) in patients with lupus nephritis, according to a federal clinical trials registry. The company said the decision was driven by s…
- EU regulators endorse Eli Lilly’s oral GLP-1 pill orforglipronThe European Medicines Agency’s human medicines committee (CHMP) has given a positive opinion on Eli Lilly’s oral GLP-1 medication, orforglipron, providing the drug with EU regulatory backing. The…